Abiraterone shows promise in prostate cancer fight, Dimebon for Alzheimer’s
A 21-patient study has shown that the drug abiraterone can stop the testosterone that feeds prostate cancer. A larger international clinical trial is underway to test the drug before it can be deemed a “miracle drug.” Also, Dimebon, once used as an antihistamine, has been found to improve cognitive abilities for Alzheimer’s patients, though researchers aren’t yet sure how. Guests: Dr. Anthony D’Amico, professor and chief of Genitourinary Radiation Oncology at Dana-Farber Cancer Institute/Brigham and Women’s Hospital, and Dr. Samuel Gandy, Associate Director of the Mount Sinai Alzheimer’s Disease Research Center, and Chair of the National Medical and Scientific Advisory Council of the Alzheimer’s Association
The World is an independent newsroom. We’re not funded by billionaires; instead, we rely on readers and listeners like you. As a listener, you’re a crucial part of our team and our global community. Your support is vital to running our nonprofit newsroom, and we can’t do this work without you. Will you support The World with a gift today? Donations made between now and Dec. 31 will be matched 1:1. Thanks for investing in our work!